Kidney transplant recipients

肾移植受者
  • 文章类型: Journal Article
    甲氧苄啶-磺胺甲恶唑(TMP-SMX)用于预防吉罗韦西肺孢子虫肺炎(PJP)的给药已被证明在接受肾移植的个体中是非常有效的。然而,与这种治疗相关的严重不良反应的可能性不容忽视,最佳剂量方案的确定仍然是一个研究问题。本研究评估了低剂量TMP-SMX预防肾移植患者PJP的有效性,并对PJP感染患者的临床特征和流行病学趋势进行了分析。
    这项回顾性分析研究了2017年至2020年1763名肾移植受者的电子病历。这些患者最初服用每日半强度TMP-SMX(40mg/200mg),在3-51个月的随访期间评估了该方案的疗效。
    在我们的PJP预防和调整策略下,24例患者感染PJP。在我们的研究中,PJP感染的总发病率为1.36%,与以前发表的研究结果证实了这一点。在这24名患者中,高达87.5%的患者因肌酐增加或其他不良反应而调整了剂量,最常见的剂量是每日1/4强度TMP-SMX(20mg/100mg).TMP-SMX预防成功推迟和分配了PJP的发作,从移植到发生PJP的平均持续时间为13.50±7.11个月。
    每日服用半强度TMP-SMX可有效预防PJP,延长这种药物的预防可能会降低感染的发生率。
    UNASSIGNED: The administration of trimethoprim-sulfamethoxazole (TMP-SMX) for the prophylaxis of Pneumocystis jirovecii pneumonia (PJP) has proven to be highly efficacious in individuals who have undergone kidney transplantation. Nevertheless, the potential for severe adverse reactions associated with this treatment cannot be overlooked, and the determination of an optimal dosage regimen continues to be a matter of investigation. The current study evaluated the effectiveness of low-dose TMP-SMX for PJP prophylaxis in kidney transplant patients and conducted an analysis of the clinical characteristics and epidemiological trends in patients with PJP infection.
    UNASSIGNED: This retrospective analysis studied electronic medical records of 1763 kidney transplant recipients from 2017 to 2020. These patients were initially prescribed a daily half-strength TMP-SMX (40 mg/200 mg), and the efficacy of this regimen was assessed during a follow-up period of 3-51 months.
    UNASSIGNED: Under our PJP prevention and adjustment strategy, 24 patients were infected with PJP. The overall morbidity of PJP infection in our study was 1.36%, corroborates with findings from previously published studies. Among these 24 patients, up to 87.5% had their dosage adjusted due to increased creatinine or other adverse reactions, the most frequent dose was daily quarter-strength TMP-SMX (20 mg/100 mg). TMP-SMX prophylaxis successfully postponed and distributed the onset of PJP, with the mean duration from transplantation to the occurrence of PJP being 13.50±7.11 months.
    UNASSIGNED: Daily administration of half-strength TMP-SMX can effectively prevent PJP, and prolonging prophylaxis with this medication may potentially reduce the incidence of infection.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    背景:肾移植受者(KTR)在感染COVID-19后进展为严重感染的风险较高。我们对SARS-CoV-2Omicron变体的KTRs的危险因素和多病原体感染进行了研究。
    方法:对KTRs进行了全面的病因评估。只要可行,他们还接受了支气管镜检查和支气管肺泡灌洗,以实现宏基因组下一代测序(mNGS),理想情况下在入院后48小时的窗口内。我们对COVID-19病毒变种Omicron的KTRs病原体和危险因素进行了回顾性分析。
    结果:我们在研究中纳入了30名患者,其中16例表现为单一感染COVID-19,14例表现为共同感染,主要与肺孢子虫jirovecii。值得注意的是,与中度患者相比,重度患者的C反应蛋白(CRP)和白细胞介素-6水平显著升高(P<0.05).此外,病情进展的个体基线血清肌酐水平明显高于无此类进展的个体(P<0.05).心力衰竭的存在,肾功能不全急性加重,由于SARS-CoV-2Omicron变体,机会性感染史与更高的恶化和入院可能性显着相关,与对照组比较(P<0.05)。在随后的后续分析中,全因再住院率为21.4%,肺孢子虫感染占这些病例的一半。
    结论:在KTR中,观察到47%的显著合并感染率,在这些情况下,肺孢子虫成为主要病原体。心力衰竭的发展,慢性肾功能不全急性加重,和先前的机会性感染史已被确定为可能导致KTRs临床恶化的潜在危险因素.此外,肺孢子虫感染已被确定为影响该患者人群全因再住院率的关键因素。
    BACKGROUND: Kidney transplant recipients (KTRs) are at an elevated risk of progressing to severe infections upon contracting COVID-19. We conducted a study on risk factors and multi-pathogen infections in KTRs with SARS-CoV-2 Omicron variant.
    METHODS: KTRs were subjected to a thorough etiological evaluation. Whenever feasible, they were also provided with bronchoscopy and bronchoalveolar lavage to enable metagenomic next-generation sequencing (mNGS), ideally within a 48-hour window post-admission. We performed a retrospective analysis for pathogens and risk factors of KTRs with the COVID-19 virus variant Omicron.
    RESULTS: We included thirty patients in our study, with sixteen exhibiting single infection of COVID-19 and fourteen experiencing co-infections, predominantly with Pneumocystis jirovecii. Notably, patients with severe cases demonstrated significantly elevated levels of C-reactive protein (CRP) and interleukin-6 compared to those with moderate cases (P < 0.05). Furthermore, individuals whose conditions progressed had markedly higher baseline serum creatinine levels than those without such progression (P < 0.05). The presence of heart failure, acute exacerbation of renal dysfunction, and a history of opportunistic infections were significantly associated with a higher likelihood of deterioration and hospital admission due to the SARS-CoV-2 Omicron variant, as compared to the control group (P < 0.05). In subsequent follow-up analysis, the all-cause rehospitalization rate was observed to be 21.4%, with Pneumocystis jirovecii infection accounting for half of these cases.
    CONCLUSIONS: Among KTRs, a significant coinfection rate of 47% was observed, with Pneumocystis jirovecii emerging as the predominant pathogen in these cases. The development of heart failure, acute exacerbation of chronic renal dysfunction, and a prior history of opportunistic infections have been identified as potential risk factors that may contribute to clinical deterioration in KTRs. Additionally, Pneumocystis jirovecii infection has been established as a critical factor influencing the rate of all-cause rehospitalization within this patient population.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    目的:由于营养状况等多种因素,肾移植受者骨折的风险很高,甲状旁腺功能亢进,酸中毒和类固醇给药。目前的荟萃分析旨在全面分析肾移植受者骨折的发生率和危险因素。
    方法:在Embase上进行系统搜索,WebofScience,PubMed和Cochrane图书馆直到2023年11月才进行。使用RStudio软件分析数据。
    结果:28项符合条件的研究纳入分析,包括310530例肾移植受者。骨折的合并发生率通常为10%(95%置信区间[CI]:7%-13%)。当按地区划分时,进一步观察到,欧洲的骨折合并发生率为13%(95%CI:9%-17%),北美11%(95%CI:6%-16%),亚洲7%(95%CI:3%-11%)。关于风险因素,汇总分析显示,接受者的年龄(风险比[HR]=1.50,95%CI:1.17-1.91),女性(HR=1.45,95%CI:1.36-1.53),移植前糖尿病(HR=1.76,95%CI:1.58-1.97),移植前骨折史(HR=2.28,95%CI:1.86-2.78),透析时间(HR=1.09,95%CI:1.01-1.17)和死亡供者(HR=1.21,95%CI:1.05-1.39)与较高的骨折风险相关.纳入研究的总体质量是可以接受的,除受者年龄与骨折发生率之间的分析外,不存在发表偏倚;进一步修剪填充法显示受者年龄与骨折发生率呈相关趋势,但无统计学意义。
    结论:肾移植受者的合并骨折发生率达到10%,这与接受者的年龄有关,女性性别,移植前糖尿病或骨折史,透析持续时间和减少供体。
    OBJECTIVE: Kidney transplant recipients are at high risk of fracture due to many factors such as nutritional status, hyperparathyroidism, acidosis and steroid administration. The current meta-analysis aimed to comprehensively analyse the incidence and risk factors of fracture in kidney transplant recipients.
    METHODS: A systematic search on Embase, Web of Science, PubMed and Cochrane Library until November 2023 was performed. RStudio software was used to analyse data.
    RESULTS: Twenty-eight eligible studies containing 310 530 kidney transplant recipients were included in the analysis. The pooled incidence of fracture was 10% (95% confidence interval [CI]: 7%-13%) generally. When divided by regions, it was further observed that the pooled incidence of fracture was 13% (95% CI: 9%-17%) in Europe, 11% (95% CI: 6%-16%) in North America, 7% (95% CI: 3%-11%) in Asia. Regarding the risk factors, pooled analysis revealed that age of recipient (hazard ratio [HR] = 1.50, 95% CI: 1.17-1.91), female sex (HR = 1.45, 95% CI: 1.36-1.53), pretransplantation diabetes (HR = 1.76, 95% CI: 1.58-1.97), pretransplantation fracture history (HR = 2.28, 95% CI: 1.86-2.78), dialysis duration (HR = 1.09, 95% CI: 1.01-1.17) and deceased donor (HR = 1.21, 95% CI: 1.05-1.39) related to higher risk of fracture. The general quality of included studies was acceptable, and no publication bias existed except for the analysis between age of recipient and fracture incidence; further trim and fill method indicated age of recipient showed a correlation trend with the fracture incidence without the statistical significance.
    CONCLUSIONS: The pooled incidence of fracture reaches 10% in kidney transplant recipients, which relates to age of recipient, female sex, pretransplantation diabetes or fracture history, dialysis duration and decease donor.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    2020年初2019年冠状病毒病(COVID-19)的突然爆发对人类生命构成了巨大威胁,并在全球范围内造成了经济动荡。肾移植受者(KTR)在COVID-19大流行期间由于使用免疫抑制剂而变得容易感染,导致住院率和死亡率增加。虽然目前疫情有所缓解,COVID-19的长期存在仍然严重威胁着免疫力低下的KTRs的生命和健康。Omicron变体,严重急性呼吸道综合症冠状病毒2(SARS-CoV-2)的高传染性但致病性较低的菌株,引起移植医生对管理诊断为这种变异的KTR的担忧。然而,目前,对于感染该变种的KTRs,目前尚无明确统一的护理指南.因此,我们旨在总结目前对可治疗KTRs中Omicron变异型感染的药物的研究,并探讨调整免疫治疗策略以增强其对疫苗反应性的潜力.在这里,我们讨论了自COVID-19出现以来KTRs的情况,并重点讨论了自Omicron变种爆发以来KTRs的各种预防和治疗策略。我们希望在存在长期COVID-19变异的情况下帮助医生管理KTR。
    The sudden outbreak of coronavirus disease 2019 (COVID-19) in early 2020 posed a massive threat to human life and caused an economic upheaval worldwide. Kidney transplant recipients (KTRs) became susceptible to infection during the COVID-19 pandemic owing to their use of immunosuppressants, resulting in increased hospitalization and mortality rates. Although the current epidemic situation is alleviated, the long-term existence of COVID-19 still seriously threatens the life and health of KTRs with low immunity. The Omicron variant, a highly infectious but less-pathogenic strain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has raised concerns among transplant physicians regarding managing KTRs diagnosed with this variant. However, currently, there are no clear and unified guidelines for caring for KTRs infected with this variant. Therefore, we aimed to summarize the ongoing research on drugs that can treat Omicron variant infections in KTRs and explore the potential of adjusting immunotherapy strategies to enhance their responsiveness to vaccines. Herein, we discuss the situation of KTRs since the emergence of COVID-19 and focus on various prevention and treatment strategies for KTRs since the Omicron variant outbreak. We hope to assist physicians in managing KTRs in the presence of long-term COVID-19 variants.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    背景:肺孢子菌肺炎(PCP)是一种危及生命的肺部真菌感染,主要影响免疫功能低下的个体,包括肾移植受者.近年来,在这一弱势群体中,PCP的发病率不断上升,导致移植物丢失和死亡率增加。免疫抑制,这对移植接受者来说是必不可少的,增加对病毒和机会性感染的易感性,放大临床挑战。同时,2019年冠状病毒病的全球影响(COVID-19),由严重急性呼吸综合征冠状病毒2(SARS-CoV-2)引起,已经深刻了。肾移植受者在感染SARS-CoV-2时面临严重的后果,通常需要重症监护。在这种情况下,COVID-19和PCP的共感染代表了一种复杂的临床情况,需要精确的管理策略,涉及免疫抑制和免疫激活之间的微妙平衡。尽管有肾移植受者COVID-19和PCP管理的病例报告,关于如何解决这些感染同时发生时的指导仍然有限。
    方法:我们遇到了4例肾移植患者并发COVID-19和PCP感染。这些患者接受综合治疗,包括调整其维持免疫抑制方案,抗肺囊虫病治疗,治疗COVID-19和其他感染,以及对症和支持性治疗。经过这种多方面的治疗策略,所有这些患者均有显著改善,且结局良好.
    结论:我们已经成功地治疗了4名同时感染COVID-19和PCP的肾移植受者。虽然PCP是免疫抑制治疗的已知并发症,其在COVID-19患者中的发病率突出了双重感染的复杂性。我们的研究结果表明,定制的免疫抑制方案,加上抗病毒和抗菌治疗,在这种情况下可以导致临床改善。需要进一步的研究来完善风险评估和治疗策略,这将最终加强对这一弱势群体的照顾。
    BACKGROUND: Pneumocystis pneumonia (PCP) is a life-threatening pulmonary fungal infection that predominantly affects immunocompromised individuals, including kidney transplant recipients. Recent years have witnessed a rising incidence of PCP in this vulnerable population, leading to graft loss and increased mortality. Immunosuppression, which is essential in transplant recipients, heightens susceptibility to viral and opportunistic infections, magnifying the clinical challenge. Concurrently, the global impact of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been profound. Kidney transplant recipients have faced severe outcomes when infected with SARS-CoV-2, often requiring intensive care. Co-infection with COVID-19 and PCP in this context represents a complex clinical scenario that requires precise management strategies, involving a delicate balance between immunosuppression and immune activation. Although there have been case reports on management of COVID-19 and PCP in kidney transplant recipients, guidance on how to tackle these infections when they occur concurrently remains limited.
    METHODS: We have encountered four kidney transplant recipients with concurrent COVID-19 and PCP infection. These patients received comprehensive treatment that included adjustment of their maintenance immunosuppressive regimen, anti-pneumocystis therapy, treatment for COVID-19 and other infections, and symptomatic and supportive care. After this multifaceted treatment strategy, all of these patients improved significantly and had favorable outcomes.
    CONCLUSIONS: We have successfully managed four kidney transplant recipients co-infected with COVID-19 and PCP. While PCP is a known complication of immunosuppressive therapy, its incidence in patients with COVID-19 highlights the complexity of dual infections. Our findings suggest that tailored immunosuppressive regimens, coupled with antiviral and antimicrobial therapies, can lead to clinical improvement in such cases. Further research is needed to refine risk assessment and therapeutic strategies, which will ultimately enhance the care of this vulnerable population.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    UNASSIGNED: No research has yet been done on social support\'s influence on the association between illness perception and psychosocial adaptation among young and middle-aged kidney transplant recipients in China. Accordingly, it remains unclear how medical personnel can assist patients in successfully adjusting to the early postoperative period and improving their health.
    UNASSIGNED: This study sought to explore the influence of illness perception and social support on the psychosocial adaptation of young and middle-aged recipients of kidney transplants in China during the early postoperative period.
    UNASSIGNED: This study adopted a cross-sectional design. The study included 236 young and middle-aged kidney transplant recipients from a tertiary hospital in China. Demographic and disease-related data were collected. Additionally, the Psychosocial Adjustment to Illness Scale-Self-Report, the Brief Illness Perception Questionnaire, and the Multidimensional Scale of Perceived Social Support were used to assess participants\' psychosocial adaptation, illness perception, and social support, respectively. The model was examined using descriptive analysis, Pearson\'s correlation analysis, hierarchical multiple regression analysis, and the PROCESS Macro in SPSS 26.0.
    UNASSIGNED: A total of 176 (74.56%) participants reported an average psychosocial adaptation score >50, which is relatively negative. Marital status, education level, residence, per capita monthly income (in Chinese yuan), medical insurance, work status, post-transplant time, body mass index, creatinine status, and complications were all related to psychosocial adaptation (p < 0.05). The more negative their illness perception and the worse their social support, the worse the psychosocial adaptation of young and middle-aged kidney transplant recipients. Further, the effect of illness perception on psychosocial adaptation was partially mediated by social support (36.56%).
    UNASSIGNED: In general, the psychosocial adaption level of young and middle-aged kidney transplant recipients was negative during the early postoperative period. Healthcare teams should assist patients in building a positive illness perception shortly following kidney transplantation, while also providing psychological care and support to help them cope with the onset of psychosocial issues.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    未经证实:建议使用第三种mRNA疫苗加强剂,以提高肾移植受者(KTRs)对SARS-CoV-2的免疫力。然而,在KTR中通过第三剂灭活加强疫苗引起的针对SARS-CoV-2祖先株以及Delta和Omicron变体的免疫力仍然未知。
    未经鉴定:与血细胞计数有关的血液参数,肝功能,肾功能,从实验室检查中对心脏损伤和免疫力进行了临床研究。使用酶联免疫吸附测定法检测SARS-CoV-2特异性抗体IgG滴度。使用干扰素-γ酶联免疫斑点测定法分析细胞免疫。
    UNASSIGNED:结果表明,同源灭活疫苗加强后,KTRs和健康志愿者(HVs)中没有严重的不良反应和临床实验室生物标志物的明显变化。与第二次疫苗接种相比,第三次剂量的灭活疫苗加强剂显着增加了KTR和HV中的抗祖先刺突三聚体IgG和抗祖先受体结合域(RBD)IgG滴度。然而,第三次给药后,KTRs和HV的抗Delta-RBD-IgG和抗Omicron-RBD-IgG滴度显著低于抗Ancestral-RBD-IgG滴度.值得注意的是,只有25.6%(10/39)和10.3%(4/39)的KTRs在加强后对抗Delta-RBD-IgG和抗Omicron-RBD-IgG具有血清阳性,显着低于HV(抗Delta-RBD-IgG:100%,抗Omicron-RBD-IgG:77.8%)。与第二剂量相比,加强后KTRs的祖先菌株核衣壳蛋白和尖峰特异性T细胞频率没有显着增加,明显低于HV。此外,33.3%(12/36),14.3%(3/21)和14.3%(3/21)的KTRs对祖先菌株和Delta和Omicron穗特异性T细胞呈阳性,显着低于HV(祖先:80.8%,三角洲:53.8%,和Omicron:57.7%)。
    UNASSIGNED:第三剂灭活加强疫苗可能显着提高KTR中针对祖先菌株的体液免疫,而KTR中针对Delta和Omicron变体的体液和细胞免疫仍然较差。
    A third mRNA vaccine booster is recommended to improve immunity against SARS-CoV-2 in kidney transplant recipients (KTRs). However, the immunity against SARS-CoV-2 Ancestral strain and Delta and Omicron variants elicited by the third dose of inactivated booster vaccine in KTRs remains unknown.
    The blood parameters related to blood cells count, hepatic function, kidney function, heart injury and immunity were explored clinically from laboratory examinations. SARS-CoV-2 specific antibody IgG titer was detected using an enzyme-linked immunosorbent assay. Cellular immunity was analyzed using interferon-γ enzyme-linked immunospot assay.
    The results showed that there were no severe adverse effects and apparent changes of clinical laboratory biomarkers in KTRs and healthy volunteers (HVs) after homologous inactivated vaccine booster. A third dose of inactivated vaccine booster significantly increased anti-Ancestral-spike-trimer-IgG and anti-Ancestral-receptor binding domain (RBD)-IgG titers in KTRs and HVs compared with the second vaccination. However, the anti-Delta-RBD-IgG and anti-Omicron-RBD-IgG titers were significantly lower than anti-Ancestral-RBD-IgG titer in KTRs and HVs after the third dose. Notably, only 25.6% (10/39) and 10.3% (4/39) of KTRs had seropositivity for anti-Delta-RBD-IgG and anti-Omicron-RBD-IgG after booster, which were significantly lower than HVs (anti-Delta-RBD-IgG: 100%, anti-Omicron-RBD-IgG: 77.8%). Ancestral strain nucleocapsid protein and spike specific T cell frequency after booster was not significantly increased in KTRs compared with the second dose, significantly lower than that in HVs. Moreover, 33.3% (12/36), 14.3% (3/21) and 14.3% (3/21) of KTRs were positive for the Ancestral strain and Delta and Omicron spike-specific T cells, which were significantly lower than HVs (Ancestral: 80.8%, Delta: 53.8%, and Omicron: 57.7%).
    A third dose of inactivated booster vaccine may significantly increase humoral immunity against the Ancestral strain in KTRs, while humoral and cellular immunity against the Delta and Omicron variants were still poor in KTRs.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    Kidney transplantation is currently the first choice of treatment for various types of end-stage renal failure, but there are major limitations in the application of immunosuppressive protocols after kidney transplantation. When the dose of immunosuppressant is too low, graft rejection occurs easily, while a dose that is too high can lead to graft loss. Therefore, it is very important to explore the immune status of patients receiving immunosuppressive agents after kidney transplantation. To compare the immune status of the recipient\'s whole peripheral blood before and after receipt of immunosuppressive agents, we used single-cell cytometry by time-of-flight (CyTOF) to detect the peripheral blood immune cells in five kidney transplant recipients (KTRs) from the Department of Organ Transplantation of Zhujiang Hospital of Southern Medical University before and after receiving immunosuppressive agents. Based on CyTOF analysis, we detected 363,342 live single immune cells. We found that the immune cell types of the KTRs before and after receipt of immunosuppressive agents were mainly divided into CD4+ T cells, CD8+ T cells, B cells, NK cells/γδ T cells, monocytes/macrophages, granulocytes, and dendritic cells (DCs). After further reclustering of the above cell types, it was found that the immune cell subclusters in the peripheral blood of patients underwent major changes after receipt of immunosuppressants. After receiving immunosuppressive therapy, the peripheral blood of KTRs had significantly increased levels of CD57+NK cells and significantly decreased levels of central memory CD4+ T cells, follicular helper CD4+ T cells, effector CD8+ T cells, effector memory CD8+ T cells and naive CD8+ T cells. This study used CyTOF to classify immune cells in the peripheral blood of KTRs before and after immunosuppressive treatment, further compared differences in the proportions of the main immune cell types and immune cell subgroups before and after receipt of immunosuppressants, and provided relatively accurate information for assessment and treatment strategies for KTRs.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    先前的研究表明,过渡护理降低了并发症发生率和再入院率,并改善了肾移植患者的生活质量,然而,事实上,肾移植受者没有标准的评估指标,现有指标的科学性值得商榷。因此,这项研究的目的是构建评估指标体系,以评估肾脏移植受者的过渡期护理效果。
    基于奥马哈系统,通过文献综述和半结构化访谈,初步制定了肾移植受者过渡期护理效果评价指标体系.对19名专家进行了两轮对应,并采用层次分析法(AHP)计算了所有指标的权重。
    五个一级指标,16个二级指数,在初始评价指标体系中选择了48个三级指标。两轮专家咨询的权威系数为0.90,指标协调系数为0.24至0.34。
    建立的肾移植受者过渡期护理效果评价指标体系科学可靠。此外,这将是一种潜在的方法,用于评估肾移植受者接受进一步检查后的过渡期护理的效果.
    Previous studies showed that transitional care reduces the complication rate and readmission rate and improves the quality of life in kidney transplant receipts, nevertheless, in fact there are no standard evaluation indexes and debatable scientific of existing indexes in kidney transplant recipients. Therefore, the aim of this study was to construct an evaluation index system to assess the effects of transitional care in kidney transplant recipients.
    Based on Omaha system, an initial evaluation index system about the effects of transitional care in kidney transplant recipients was drafted by the literature review and semi-structured interview. Two rounds of correspondence were conducted in 19 experts and the analytic hierarchy process (AHP) was used to calculate the weights of all indexes.
    Five first-level indexes, sixteen second-level indexes, and forty-eight third-level indexes were selected in the initial evaluation index system. The authority coefficient of two-round expert consultations was 0.90 and coordination coefficients of indexes ranged from 0.24 to 0.34.
    The established evaluation index system for the effectiveness of transitional care for kidney transplant recipients was scientific and reliable. Furthermore, it would be a potential method to evaluate effects of transitional care in kidney transplant recipients after further examination.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

       PDF(Pubmed)

  • 文章类型: Journal Article
    Elevated parathyroid hormone (PTH) concentrations were reported to be associated with chronic renal allograft failure. However, measurements of PTH are challenging, because PTH can occur either as non-oxidized (n-ox) or oxidized (ox) PTH. Only n-ox PTH is a PTH receptor agonist. The intact PTH (iPTH) concentrations measured routinely in clinical practice, however, equals non-oxidized PTH (n-oxPTH) plus oxidized PTH (oxPTH). In CKD patients, the majority of the circulating PTH is oxidized. We measured iPTH, oxPTH and n-oxPTH at study entry in 600 kidney transplant recipients (KTRs). They were followed for graft loss for 3 years. Graft loss was defined as need for initiation of renal replacement therapy. Thirty-eight patients had graft loss during the 3 years follow-up. OxPTH correlated very well with iPTH (R2 = 0.997, p < 0.0001), whereas the correlation between n-oxPTH and iPTH was much weaker (R2 = 0.762, p < 0.0001). Compared to KTRs without graft loss, KTRs with graft loss had significantly higher levels of iPTH, oxPTH, and n-oxPTH (p < 0.0001 in all cases). After adjusting for confounding factors in cox proportional hazards analysis, only n-oxPTH, but not oxPTH neither iPTH, was significantly associated with graft loss (Hazard ratio (HR): 1.02, 95% CI: 1.01-1.03, p = 1.84 × 10-3). The very close correlation between oxPTH and iPTH measurements suggests that conventional iPTH measurements most likely describe oxidative stress rather than PTH bioactivity. Only non-oxidized PTH but not oxidized PTH nor intact PTH is associated with graft loss in stable kidney transplant recipients.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

公众号